Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa

To prevent sexually-acquired HIV-1 infection by immunoprophylaxis, effective concentrations of broadly neutralizing antibodies are likely needed at mucosal sites of exposure. Here, we examine the biodistribution of monoclonal antibody VRC01 and its extended half-life variant, VRC01LS, in colorectal...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 15; no. 1; pp. 10332 - 16
Main Authors Lemos, Maria P., Astronomo, Rena D., Huang, Yunda, Narpala, Sandeep, Prabhakaran, Madhu, Mann, Philipp, Paez, Carmen A., Lu, Yiwen, Mize, Gregory J., Glantz, Hayley, Westerberg, Katharine, Colegrove, Hunter, Smythe, Kimberly S., Lin, Minggang, Pierce, Robert H., Hutter, Julia, Frank, Ian, Mascola, John R., McDermott, Adrian B., Bekker, Linda-Gail, McElrath, M. Juliana
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 28.11.2024
Nature Publishing Group
Nature Portfolio
Subjects
13/1
13/106
631/250/251/1567
631/250/2520
631/250/347
692/699/255/1901
82/51
Adult
Antibodies
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - pharmacokinetics
Antibodies, Neutralizing - immunology
Biodistribution
Biological effects
Blood levels
Broadly Neutralizing Antibodies - immunology
Disease transmission
Female
Genital tract
Half-Life
HIV
HIV Antibodies - immunology
HIV Infections - immunology
HIV Infections - prevention & control
HIV Infections - virology
HIV-1 - immunology
Human immunodeficiency virus
Humanities and Social Sciences
Humans
Immunoprophylaxis
Intestinal Mucosa - immunology
Intestinal Mucosa - metabolism
Intravenous infusion
Lamina propria
Male
Middle Aged
Monoclonal antibodies
Mucosa
Mucous Membrane - immunology
Mucous Membrane - metabolism
Mucous Membrane - virology
multidisciplinary
Neutralizing
Rectum
Rectum - virology
Science
Science (multidisciplinary)
Secretions
Sexually transmitted diseases
STD
Stroma
Tissue Distribution
Tissues
Vagina - immunology
Vagina - virology
Young Adult
Online AccessGet full text

Cover

Abstract To prevent sexually-acquired HIV-1 infection by immunoprophylaxis, effective concentrations of broadly neutralizing antibodies are likely needed at mucosal sites of exposure. Here, we examine the biodistribution of monoclonal antibody VRC01 and its extended half-life variant, VRC01LS, in colorectal and genitourinary tracts of healthy adults 1-52 weeks after intravenous infusion. At 1-2 weeks, VRC01LS levels are ~3-4 times higher than VRC01 in serum ( p  = 0.048), rectal ( p  = 0.067), vaginal ( p  = 0.003) and cervical tissues ( p  = 0.003); these differences increase over time. Both antibodies primarily localize within rectal lamina propria and cervicovaginal stroma, with limited and variable epithelial distribution. Although 8-28% of serum mAb levels reach mucosal tissues, <3% are in seminal and rectal secretions. Elimination half-lives in mucosal tissues are 20-28 days for VRC01 and 51-68 days for VRC01LS. Thus, VRC01LS infusion achieves higher, sustained concentrations in human mucosal tissues than VRC01, supporting the future investigation of potent, long-acting LS-modified antibodies to prevent HIV-1. Antibody immunoprophylaxis for HIV-1 will require effective concentration of biologics at mucosal sites of exposure for effectivity. Here the authors show that infused Fc-modified VRC01LS antibody has increased levels in blood, in the female genital tract and male rectal tissue, compared to native antibody VRC01. VRC01LS is detectable for more than year at the sites of sexual HIV transmission.
AbstractList To prevent sexually-acquired HIV-1 infection by immunoprophylaxis, effective concentrations of broadly neutralizing antibodies are likely needed at mucosal sites of exposure. Here, we examine the biodistribution of monoclonal antibody VRC01 and its extended half-life variant, VRC01LS, in colorectal and genitourinary tracts of healthy adults 1-52 weeks after intravenous infusion. At 1-2 weeks, VRC01LS levels are ~3-4 times higher than VRC01 in serum (p = 0.048), rectal (p = 0.067), vaginal (p = 0.003) and cervical tissues (p = 0.003); these differences increase over time. Both antibodies primarily localize within rectal lamina propria and cervicovaginal stroma, with limited and variable epithelial distribution. Although 8-28% of serum mAb levels reach mucosal tissues, <3% are in seminal and rectal secretions. Elimination half-lives in mucosal tissues are 20-28 days for VRC01 and 51-68 days for VRC01LS. Thus, VRC01LS infusion achieves higher, sustained concentrations in human mucosal tissues than VRC01, supporting the future investigation of potent, long-acting LS-modified antibodies to prevent HIV-1.To prevent sexually-acquired HIV-1 infection by immunoprophylaxis, effective concentrations of broadly neutralizing antibodies are likely needed at mucosal sites of exposure. Here, we examine the biodistribution of monoclonal antibody VRC01 and its extended half-life variant, VRC01LS, in colorectal and genitourinary tracts of healthy adults 1-52 weeks after intravenous infusion. At 1-2 weeks, VRC01LS levels are ~3-4 times higher than VRC01 in serum (p = 0.048), rectal (p = 0.067), vaginal (p = 0.003) and cervical tissues (p = 0.003); these differences increase over time. Both antibodies primarily localize within rectal lamina propria and cervicovaginal stroma, with limited and variable epithelial distribution. Although 8-28% of serum mAb levels reach mucosal tissues, <3% are in seminal and rectal secretions. Elimination half-lives in mucosal tissues are 20-28 days for VRC01 and 51-68 days for VRC01LS. Thus, VRC01LS infusion achieves higher, sustained concentrations in human mucosal tissues than VRC01, supporting the future investigation of potent, long-acting LS-modified antibodies to prevent HIV-1.
To prevent sexually-acquired HIV-1 infection by immunoprophylaxis, effective concentrations of broadly neutralizing antibodies are likely needed at mucosal sites of exposure. Here, we examine the biodistribution of monoclonal antibody VRC01 and its extended half-life variant, VRC01LS, in colorectal and genitourinary tracts of healthy adults 1-52 weeks after intravenous infusion. At 1-2 weeks, VRC01LS levels are ~3-4 times higher than VRC01 in serum ( p  = 0.048), rectal ( p  = 0.067), vaginal ( p  = 0.003) and cervical tissues ( p  = 0.003); these differences increase over time. Both antibodies primarily localize within rectal lamina propria and cervicovaginal stroma, with limited and variable epithelial distribution. Although 8-28% of serum mAb levels reach mucosal tissues, <3% are in seminal and rectal secretions. Elimination half-lives in mucosal tissues are 20-28 days for VRC01 and 51-68 days for VRC01LS. Thus, VRC01LS infusion achieves higher, sustained concentrations in human mucosal tissues than VRC01, supporting the future investigation of potent, long-acting LS-modified antibodies to prevent HIV-1. Antibody immunoprophylaxis for HIV-1 will require effective concentration of biologics at mucosal sites of exposure for effectivity. Here the authors show that infused Fc-modified VRC01LS antibody has increased levels in blood, in the female genital tract and male rectal tissue, compared to native antibody VRC01. VRC01LS is detectable for more than year at the sites of sexual HIV transmission.
Abstract To prevent sexually-acquired HIV-1 infection by immunoprophylaxis, effective concentrations of broadly neutralizing antibodies are likely needed at mucosal sites of exposure. Here, we examine the biodistribution of monoclonal antibody VRC01 and its extended half-life variant, VRC01LS, in colorectal and genitourinary tracts of healthy adults 1-52 weeks after intravenous infusion. At 1-2 weeks, VRC01LS levels are ~3-4 times higher than VRC01 in serum (p = 0.048), rectal (p = 0.067), vaginal (p = 0.003) and cervical tissues (p = 0.003); these differences increase over time. Both antibodies primarily localize within rectal lamina propria and cervicovaginal stroma, with limited and variable epithelial distribution. Although 8-28% of serum mAb levels reach mucosal tissues, <3% are in seminal and rectal secretions. Elimination half-lives in mucosal tissues are 20-28 days for VRC01 and 51-68 days for VRC01LS. Thus, VRC01LS infusion achieves higher, sustained concentrations in human mucosal tissues than VRC01, supporting the future investigation of potent, long-acting LS-modified antibodies to prevent HIV-1.
To prevent sexually-acquired HIV-1 infection by immunoprophylaxis, effective concentrations of broadly neutralizing antibodies are likely needed at mucosal sites of exposure. Here, we examine the biodistribution of monoclonal antibody VRC01 and its extended half-life variant, VRC01LS, in colorectal and genitourinary tracts of healthy adults 1-52 weeks after intravenous infusion. At 1-2 weeks, VRC01LS levels are ~3-4 times higher than VRC01 in serum (p = 0.048), rectal (p = 0.067), vaginal (p = 0.003) and cervical tissues (p = 0.003); these differences increase over time. Both antibodies primarily localize within rectal lamina propria and cervicovaginal stroma, with limited and variable epithelial distribution. Although 8-28% of serum mAb levels reach mucosal tissues, <3% are in seminal and rectal secretions. Elimination half-lives in mucosal tissues are 20-28 days for VRC01 and 51-68 days for VRC01LS. Thus, VRC01LS infusion achieves higher, sustained concentrations in human mucosal tissues than VRC01, supporting the future investigation of potent, long-acting LS-modified antibodies to prevent HIV-1.
To prevent sexually-acquired HIV-1 infection by immunoprophylaxis, effective concentrations of broadly neutralizing antibodies are likely needed at mucosal sites of exposure. Here, we examine the biodistribution of monoclonal antibody VRC01 and its extended half-life variant, VRC01LS, in colorectal and genitourinary tracts of healthy adults 1-52 weeks after intravenous infusion. At 1-2 weeks, VRC01LS levels are ~3-4 times higher than VRC01 in serum (p = 0.048), rectal (p = 0.067), vaginal (p = 0.003) and cervical tissues (p = 0.003); these differences increase over time. Both antibodies primarily localize within rectal lamina propria and cervicovaginal stroma, with limited and variable epithelial distribution. Although 8-28% of serum mAb levels reach mucosal tissues, <3% are in seminal and rectal secretions. Elimination half-lives in mucosal tissues are 20-28 days for VRC01 and 51-68 days for VRC01LS. Thus, VRC01LS infusion achieves higher, sustained concentrations in human mucosal tissues than VRC01, supporting the future investigation of potent, long-acting LS-modified antibodies to prevent HIV-1.Antibody immunoprophylaxis for HIV-1 will require effective concentration of biologics at mucosal sites of exposure for effectivity. Here the authors show that infused Fc-modified VRC01LS antibody has increased levels in blood, in the female genital tract and male rectal tissue, compared to native antibody VRC01. VRC01LS is detectable for more than year at the sites of sexual HIV transmission.
ArticleNumber 10332
Author Lin, Minggang
Paez, Carmen A.
Hutter, Julia
Lemos, Maria P.
Glantz, Hayley
Narpala, Sandeep
Pierce, Robert H.
Westerberg, Katharine
Lu, Yiwen
Mascola, John R.
Mize, Gregory J.
Smythe, Kimberly S.
Frank, Ian
Huang, Yunda
Astronomo, Rena D.
Bekker, Linda-Gail
Colegrove, Hunter
McDermott, Adrian B.
McElrath, M. Juliana
Prabhakaran, Madhu
Mann, Philipp
Author_xml – sequence: 1
  givenname: Maria P.
  orcidid: 0000-0002-3530-9310
  surname: Lemos
  fullname: Lemos, Maria P.
  organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
– sequence: 2
  givenname: Rena D.
  surname: Astronomo
  fullname: Astronomo, Rena D.
  organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
– sequence: 3
  givenname: Yunda
  orcidid: 0000-0003-1546-6172
  surname: Huang
  fullname: Huang, Yunda
  organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
– sequence: 4
  givenname: Sandeep
  surname: Narpala
  fullname: Narpala, Sandeep
  organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
– sequence: 5
  givenname: Madhu
  surname: Prabhakaran
  fullname: Prabhakaran, Madhu
  organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
– sequence: 6
  givenname: Philipp
  orcidid: 0000-0001-8130-2032
  surname: Mann
  fullname: Mann, Philipp
  organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
– sequence: 7
  givenname: Carmen A.
  orcidid: 0000-0001-8640-6623
  surname: Paez
  fullname: Paez, Carmen A.
  organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
– sequence: 8
  givenname: Yiwen
  surname: Lu
  fullname: Lu, Yiwen
  organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
– sequence: 9
  givenname: Gregory J.
  surname: Mize
  fullname: Mize, Gregory J.
  organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
– sequence: 10
  givenname: Hayley
  surname: Glantz
  fullname: Glantz, Hayley
  organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
– sequence: 11
  givenname: Katharine
  surname: Westerberg
  fullname: Westerberg, Katharine
  organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
– sequence: 12
  givenname: Hunter
  orcidid: 0000-0002-6660-8460
  surname: Colegrove
  fullname: Colegrove, Hunter
  organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
– sequence: 13
  givenname: Kimberly S.
  orcidid: 0000-0002-2329-8298
  surname: Smythe
  fullname: Smythe, Kimberly S.
  organization: Clinical Research Division, Fred Hutchinson Cancer Center
– sequence: 14
  givenname: Minggang
  surname: Lin
  fullname: Lin, Minggang
  organization: Human Biology Division, Fred Hutchinson Cancer Center
– sequence: 15
  givenname: Robert H.
  surname: Pierce
  fullname: Pierce, Robert H.
  organization: Clinical Research Division, Fred Hutchinson Cancer Center
– sequence: 16
  givenname: Julia
  surname: Hutter
  fullname: Hutter, Julia
  organization: Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health
– sequence: 17
  givenname: Ian
  surname: Frank
  fullname: Frank, Ian
  organization: Perelman School of Medicine, University of Pennsylvania
– sequence: 18
  givenname: John R.
  surname: Mascola
  fullname: Mascola, John R.
  organization: ModeX Therapeutics
– sequence: 19
  givenname: Adrian B.
  surname: McDermott
  fullname: McDermott, Adrian B.
  organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
– sequence: 20
  givenname: Linda-Gail
  orcidid: 0000-0002-0755-4386
  surname: Bekker
  fullname: Bekker, Linda-Gail
  organization: Desmond Tutu HIV Centre, University of Cape Town
– sequence: 21
  givenname: M. Juliana
  orcidid: 0000-0003-2276-7117
  surname: McElrath
  fullname: McElrath, M. Juliana
  email: jmcelrat@fredhutch.org
  organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Department of Medicine, University of Washington
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39609400$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtv1DAUhS1UREvpH2CBIrFhE_ArTrxEo0JHGqkStN1aftxMPUrswU4W7a_HMykFsag3vr76zrm-Om_RSYgBEHpP8GeCWfclc8JFW2PK64Y3Ha7lK3RGMSc1aSk7-ac-RRc573A5TJKO8zfolEmBJcf4DO0vw70OFlylg6vynCftQ3kZH53PU_JmnnwMVeyrq_VdTaoA85T04B992BbN5E10D9XdjxUmm5-VD9X9POpQbSH4SQ9H1wT2UI6zjVm_Q697PWS4eLrP0e23y5vVVb25_r5efd3UljMx1RQaZnjTY7C4oZzIjhrRYYqFk23fCsEoNWA16TkQY6HtDWmlM4K4DjSz7BytF18X9U7tkx91elBRe3VsxLRVOk3eDqDASCaIdCBEy4VtjSOSCqsbo2mHcV-8Pi1e-xR_zZAnNfpsYRh0gDhnxQjjWAjasIJ-_A_dxTmFsumBYp0QHZWF-vBEzWYE9_y9P7kUgC6ATTHnBP0zQrA65K-W_FXJXx3zVwdXtohygcMW0t_ZL6h-AzsMsGc
Cites_doi 10.1016/S0165-0378(98)00086-2
10.1371/journal.ppat.1003776
10.1007/s10928-013-9332-2
10.1126/science.aag0491
10.1002/psp4.12224
10.1208/s12248-009-9157-5
10.1038/s41541-021-00305-8
10.1126/science.1187659
10.1097/QAI.0000000000002892
10.4049/jimmunol.166.5.3266
10.1371/journal.pmed.1002493
10.3389/fimmu.2021.712122
10.1038/s41598-021-02954-0
10.1371/journal.pmed.1002435
10.1016/j.jim.2017.07.009
10.4049/jimmunol.2100253
10.1164/ajrccm.164.supplement_2.2106065
10.1111/aji.12230
10.1038/s41467-022-28727-5
10.3389/fcimb.2021.733619
10.1016/j.immuni.2007.01.007
10.1371/journal.pone.0132942
10.3389/fimmu.2019.01540
10.1038/mi.2013.120
10.3389/fimmu.2019.00144
10.1111/cei.12692
10.1208/s12248-012-9395-9
10.1136/bmjopen-2020-042247
10.1046/j.1365-2249.1996.36742.x
10.1095/biolreprod.110.090423
10.1056/NEJMoa2031738
10.1038/s41591-022-01762-x
10.1517/17425255.2015.1027682
10.1073/pnas.1012861108
10.1182/blood.V98.10.3136
10.1038/s41591-022-01953-6
10.4049/jimmunol.2000320
10.1371/journal.pone.0108954
10.1128/JVI.01361-13
10.1126/science.1192819
10.4049/jimmunol.139.9.3041
10.1093/intimm/dxg018
10.1038/nature13612
10.1083/jcb.200809122
10.1093/bioinformatics/btt456
10.1093/intimm/10.9.1289
10.1038/s41467-019-12732-2
10.1007/s11930-021-00305-8
10.1097/QAI.0b013e3182898392
10.1016/j.jim.2021.112995
10.1371/journal.pone.0245638
10.1038/bjc.1992.144
10.1242/dmm.035147
10.1172/jci146975
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7X7
7XB
88E
8AO
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
P5Z
P62
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
SOI
7X8
DOA
DOI 10.1038/s41467-024-54580-9
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One
ProQuest Central Korea
Engineering Research Database
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Chemoreception Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Advanced Technologies & Aerospace Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
AIDS and Cancer Research Abstracts
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Immunology Abstracts
Environment Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2041-1723
EndPage 16
ExternalDocumentID oai_doaj_org_article_eb93619de66746c7bd1926ca5ba2800f
39609400
10_1038_s41467_024_54580_9
Genre Journal Article
Clinical Trial, Phase I
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: U.S. Department of Health & Human Services | National Institutes of Health (NIH)
  grantid: UM1 AI068618; UM1 AI069481; UM1 AI069501; UM1 AI069534; UM1 AI068635; P30 CA015704
  funderid: https://doi.org/10.13039/100000002
– fundername: NIAID NIH HHS
  grantid: UM1 AI068614
– fundername: NIAID NIH HHS
  grantid: UM1 AI068618
– fundername: NIAID NIH HHS
  grantid: UM1 AI069501
– fundername: NIAID NIH HHS
  grantid: UM1 AI069534
– fundername: NCI NIH HHS
  grantid: P30 CA015704
– fundername: NIAID NIH HHS
  grantid: UM1 AI068635
– fundername: NIAID NIH HHS
  grantid: UM1 AI069481
GroupedDBID ---
0R~
39C
3V.
53G
5VS
70F
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
AAHBH
AAJSJ
ABUWG
ACGFO
ACGFS
ACIWK
ACMJI
ACPRK
ACSMW
ADBBV
ADFRT
ADMLS
ADRAZ
AENEX
AEUYN
AFKRA
AFRAH
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIJS
ARAPS
ASPBG
AVWKF
AZFZN
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EE.
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
KQ8
LGEZI
LK8
LOTEE
M1P
M48
M7P
M~E
NADUK
NAO
NXXTH
O9-
OK1
P2P
P62
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
SV3
TSG
UKHRP
AASML
AAYXX
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
PUEGO
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7XB
8FD
8FK
AARCD
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
SOI
7X8
ID FETCH-LOGICAL-c436t-2e53b45f0ec05241982b680206d97f766322beca1f4e1bce7fb179db61d8ea3c3
IEDL.DBID 7X7
ISSN 2041-1723
IngestDate Wed Aug 27 01:27:03 EDT 2025
Thu Jul 10 21:33:42 EDT 2025
Wed Aug 13 04:34:41 EDT 2025
Sun Aug 31 01:36:51 EDT 2025
Tue Jul 01 02:37:48 EDT 2025
Fri Feb 21 02:38:49 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2024. The Author(s).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c436t-2e53b45f0ec05241982b680206d97f766322beca1f4e1bce7fb179db61d8ea3c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-8640-6623
0000-0002-2329-8298
0000-0002-3530-9310
0000-0002-0755-4386
0000-0001-8130-2032
0000-0002-6660-8460
0000-0003-1546-6172
0000-0003-2276-7117
OpenAccessLink https://www.proquest.com/docview/3133866829?pq-origsite=%requestingapplication%
PMID 39609400
PQID 3133866829
PQPubID 546298
PageCount 16
ParticipantIDs doaj_primary_oai_doaj_org_article_eb93619de66746c7bd1926ca5ba2800f
proquest_miscellaneous_3134066253
proquest_journals_3133866829
pubmed_primary_39609400
crossref_primary_10_1038_s41467_024_54580_9
springer_journals_10_1038_s41467_024_54580_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-11-28
PublicationDateYYYYMMDD 2024-11-28
PublicationDate_xml – month: 11
  year: 2024
  text: 2024-11-28
  day: 28
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Nature communications
PublicationTitleAbbrev Nat Commun
PublicationTitleAlternate Nat Commun
PublicationYear 2024
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Takuva (CR33) 2022; 89
Gonzalez, Aguilar-Jimenez, Su, Rugeles (CR10) 2019; 10
Liu (CR53) 2016; 353
Franklin, Kutteh (CR58) 1999; 42
Ram (CR39) 2021; 16
Ledgerwood (CR36) 2015; 182
CR34
Gilbert (CR4) 2022; 28
Sobia (CR27) 2021; 11
Tzaban (CR19) 2009; 185
CR30
Ryman, Meibohm (CR18) 2017; 6
Chen, Balthasar (CR47) 2012; 14
Hladik (CR7) 2007; 26
Mahomed (CR54) 2020; 10
Pyzik (CR22) 2019; 10
Kutteh, Prince, Hammond, Kutteh, Mestecky (CR29) 1996; 104
Byrne (CR61) 2021; 11
Zhu (CR31) 2001; 166
Dubinskaya, Guthrie, Anger, Eilber, Berman (CR50) 2021; 13
Fong, Sebestyen, Yu, Gilbert, Self (CR57) 2013; 29
Prabhakaran (CR35) 2021; 491
Ko (CR12) 2014; 514
Holton (CR15) 1987; 139
Borvak (CR16) 1998; 10
McDonald (CR26) 2001; 164
Czartoski (CR56) 2020; 205
Molthoff, Pinedo, Schluper, Nijman, Boven (CR40) 1992; 65
Buchbinder (CR24) 2018; 25
Ildgruben, Sjoberg, Hammarstrom (CR59) 2003; 102
Covell (CR14) 1986; 46
Gupta (CR32) 2013; 9
Baxter, Zhu, Mackensen, Jain (CR41) 1994; 54
Bleeker, Teeling, Hack (CR51) 2001; 98
Anderson, Marathe, Pudney (CR49) 2014; 71
Walsh, Seaman (CR6) 2021; 12
Mayer (CR38) 2017; 14
Beckford-Vera (CR43) 2022; 13
Cao, Balthasar, Jusko (CR44) 2013; 40
Lemos (CR9) 2014; 9
Schneider (CR42) 2017; 450
Corey (CR3) 2021; 384
Klein (CR11) 2013; 87
Blaskewicz, Pudney, Anderson (CR48) 2011; 85
Seaton (CR55) 2021; 6
Zhou, Ghetie, Ober (CR17) 2003; 15
Wang (CR52) 2014; 7
MacDermott (CR25) 1989; 96
Cottrell, Srinivas, Kashuba (CR23) 2015; 11
Tabrizi, Bornstein, Suria (CR20) 2010; 12
Casazza (CR37) 2022; 28
Wu (CR1) 2010; 329
CR28
Patyka, Malamud, Weissman, Abrams, Kurago (CR45) 2015; 10
Li (CR21) 2011; 108
Gaudinski (CR5) 2018; 15
Zhou (CR2) 2010; 329
McElrath (CR8) 2013; 63
CR60
Cantero-Perez (CR46) 2019; 10
Carias (CR13) 2021; 207
P Sobia (54580_CR27) 2021; 11
J Liu (54580_CR53) 2016; 353
WardES Zhou (54580_CR17) 2003; 15
M Tabrizi (54580_CR20) 2010; 12
T Zhou (54580_CR2) 2010; 329
J Borvak (54580_CR16) 1998; 10
MR Gaudinski (54580_CR5) 2018; 15
S Ram (54580_CR39) 2021; 16
JR Schneider (54580_CR42) 2017; 450
F Hladik (54580_CR7) 2007; 26
54580_CR34
S Takuva (54580_CR33) 2022; 89
PB Gilbert (54580_CR4) 2022; 28
Y Chen (54580_CR47) 2012; 14
DR Beckford-Vera (54580_CR43) 2022; 13
RD Franklin (54580_CR58) 1999; 42
JE Ledgerwood (54580_CR36) 2015; 182
CD Blaskewicz (54580_CR48) 2011; 85
M Pyzik (54580_CR22) 2019; 10
X Zhu (54580_CR31) 2001; 166
JP Casazza (54580_CR37) 2022; 28
SY Ko (54580_CR12) 2014; 514
SP Buchbinder (54580_CR24) 2018; 25
Y Cao (54580_CR44) 2013; 40
K Klein (54580_CR11) 2013; 87
JT Ryman (54580_CR18) 2017; 6
A Dubinskaya (54580_CR50) 2021; 13
LT Baxter (54580_CR41) 1994; 54
WH Kutteh (54580_CR29) 1996; 104
AK Ildgruben (54580_CR59) 2003; 102
X Wu (54580_CR1) 2010; 329
DG Covell (54580_CR14) 1986; 46
J Cantero-Perez (54580_CR46) 2019; 10
DJ Anderson (54580_CR49) 2014; 71
Y Fong (54580_CR57) 2013; 29
AM Carias (54580_CR13) 2021; 207
54580_CR60
S Mahomed (54580_CR54) 2020; 10
EH Byrne (54580_CR61) 2021; 11
KE Seaton (54580_CR55) 2021; 6
YY Wang (54580_CR52) 2014; 7
S Tzaban (54580_CR19) 2009; 185
Z Li (54580_CR21) 2011; 108
ML Cottrell (54580_CR23) 2015; 11
DM McDonald (54580_CR26) 2001; 164
MJ McElrath (54580_CR8) 2013; 63
RP MacDermott (54580_CR25) 1989; 96
S Gupta (54580_CR32) 2013; 9
M Prabhakaran (54580_CR35) 2021; 491
54580_CR30
J Czartoski (54580_CR56) 2020; 205
KH Mayer (54580_CR38) 2017; 14
OD Holton (54580_CR15) 1987; 139
CF Molthoff (54580_CR40) 1992; 65
WK Bleeker (54580_CR51) 2001; 98
SR Walsh (54580_CR6) 2021; 12
SM Gonzalez (54580_CR10) 2019; 10
M Patyka (54580_CR45) 2015; 10
L Corey (54580_CR3) 2021; 384
MP Lemos (54580_CR9) 2014; 9
54580_CR28
References_xml – volume: 42
  start-page: 93
  year: 1999
  end-page: 106
  ident: CR58
  article-title: Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones
  publication-title: J. Reprod. Immunol.
  doi: 10.1016/S0165-0378(98)00086-2
– volume: 9
  start-page: e1003776
  year: 2013
  ident: CR32
  article-title: The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1003776
– volume: 40
  start-page: 597
  year: 2013
  end-page: 607
  ident: CR44
  article-title: Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies
  publication-title: J. Pharmacokinet. Pharmacodyn.
  doi: 10.1007/s10928-013-9332-2
– volume: 353
  start-page: 1045
  year: 2016
  end-page: 1049
  ident: CR53
  article-title: Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus
  publication-title: Science
  doi: 10.1126/science.aag0491
– volume: 6
  start-page: 576
  year: 2017
  end-page: 588
  ident: CR18
  article-title: Pharmacokinetics of monoclonal antibodies
  publication-title: CPT Pharmacomet. Syst. Pharm.
  doi: 10.1002/psp4.12224
– volume: 12
  start-page: 33
  year: 2010
  end-page: 43
  ident: CR20
  article-title: Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease
  publication-title: AAPS J.
  doi: 10.1208/s12248-009-9157-5
– volume: 6
  year: 2021
  ident: CR55
  article-title: Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-021-00305-8
– volume: 329
  start-page: 856
  year: 2010
  end-page: 861
  ident: CR1
  article-title: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
  publication-title: Science
  doi: 10.1126/science.1187659
– volume: 89
  start-page: 405
  year: 2022
  end-page: 413
  ident: CR33
  article-title: Infusion reactions after receiving the broadly neutralizing antibody VRC01 or placebo to reduce HIV-1 acquisition: Results from the phase 2b antibody-mediated prevention randomized trials
  publication-title: J. Acquir Immune Defic. Syndr.
  doi: 10.1097/QAI.0000000000002892
– volume: 166
  start-page: 3266
  year: 2001
  end-page: 3276
  ident: CR31
  article-title: MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.166.5.3266
– volume: 15
  start-page: e1002493
  year: 2018
  ident: CR5
  article-title: Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
  publication-title: PLoS Med.
  doi: 10.1371/journal.pmed.1002493
– volume: 12
  year: 2021
  ident: CR6
  article-title: Broadly neutralizing antibodies for HIV-1 prevention
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.712122
– volume: 11
  year: 2021
  ident: CR27
  article-title: Higher mucosal antibody concentrations in women with genital tract inflammation
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-02954-0
– volume: 14
  start-page: e1002435
  year: 2017
  ident: CR38
  article-title: Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
  publication-title: PLoS Med.
  doi: 10.1371/journal.pmed.1002435
– volume: 450
  start-page: 66
  year: 2017
  end-page: 72
  ident: CR42
  article-title: Long-term direct visualization of passively transferred fluorophore-conjugated antibodies
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2017.07.009
– volume: 207
  start-page: 505
  year: 2021
  end-page: 511
  ident: CR13
  article-title: Anatomic distribution of intravenously injected IgG takes approximately 1 week to achieve stratum corneum saturation in vaginal tissues
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.2100253
– volume: 164
  start-page: S39
  year: 2001
  end-page: S45
  ident: CR26
  article-title: Angiogenesis and remodeling of airway vasculature in chronic inflammation
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/ajrccm.164.supplement_2.2106065
– volume: 71
  start-page: 618
  year: 2014
  end-page: 623
  ident: CR49
  article-title: The structure of the human vaginal stratum corneum and its role in immune defense
  publication-title: Am. J. Reprod. Immunol.
  doi: 10.1111/aji.12230
– volume: 96
  start-page: 764
  year: 1989
  end-page: 768
  ident: CR25
  article-title: Alterations in serum immunoglobulin G subclass in patients with ulcerative colitis and Crohn's disease
  publication-title: Gastroenterology
– volume: 13
  year: 2022
  ident: CR43
  article-title: First-in-human immunoPET imaging of HIV-1 infection using (89)Zr-labeled VRC01 broadly neutralizing antibody
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-28727-5
– volume: 11
  year: 2021
  ident: CR61
  article-title: Antigen presenting cells link the female genital tract microbiome to mucosal inflammation, with hormonal contraception as an additional modulator of inflammatory signatures
  publication-title: Front. Cell Infect. Microbiol.
  doi: 10.3389/fcimb.2021.733619
– volume: 26
  start-page: 257
  year: 2007
  end-page: 270
  ident: CR7
  article-title: Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1
  publication-title: Immunity
  doi: 10.1016/j.immuni.2007.01.007
– volume: 10
  start-page: e0132942
  year: 2015
  ident: CR45
  article-title: Periluminal distribution of HIV-binding target cells and Gp340 in the oral, cervical and sigmoid/rectal mucosae: A mapping study
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0132942
– volume: 10
  start-page: 1540
  year: 2019
  ident: CR22
  article-title: The neonatal Fc receptor (FcRn): A misnomer?
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.01540
– volume: 102
  start-page: 571
  year: 2003
  end-page: 582
  ident: CR59
  article-title: Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium
  publication-title: Obstet. Gynecol.
– volume: 7
  start-page: 1036
  year: 2014
  end-page: 1044
  ident: CR52
  article-title: IgG in cervicovaginal mucus traps HSV and prevents vaginal herpes infections
  publication-title: Mucosal Immunol.
  doi: 10.1038/mi.2013.120
– volume: 10
  start-page: 144
  year: 2019
  ident: CR10
  article-title: Mucosa: Key interactions determining sexual transmission of the HIV infection
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.00144
– volume: 182
  start-page: 289
  year: 2015
  end-page: 301
  ident: CR36
  article-title: Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults
  publication-title: Clin. Exp. Immunol.
  doi: 10.1111/cei.12692
– volume: 14
  start-page: 850
  year: 2012
  end-page: 859
  ident: CR47
  article-title: Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn
  publication-title: AAPS J.
  doi: 10.1208/s12248-012-9395-9
– volume: 10
  start-page: e042247
  year: 2020
  ident: CR54
  article-title: Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2020-042247
– ident: CR60
– volume: 104
  start-page: 538
  year: 1996
  end-page: 542
  ident: CR29
  article-title: Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation
  publication-title: Clin. Exp. Immunol.
  doi: 10.1046/j.1365-2249.1996.36742.x
– volume: 85
  start-page: 97
  year: 2011
  end-page: 104
  ident: CR48
  article-title: Structure and function of intercellular junctions in human cervical and vaginal mucosal epithelia
  publication-title: Biol. Reprod.
  doi: 10.1095/biolreprod.110.090423
– volume: 384
  start-page: 1003
  year: 2021
  end-page: 1014
  ident: CR3
  article-title: Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2031738
– volume: 28
  start-page: 1022
  year: 2022
  end-page: 1030
  ident: CR37
  article-title: Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-01762-x
– volume: 11
  start-page: 893
  year: 2015
  end-page: 905
  ident: CR23
  article-title: Pharmacokinetics of antiretrovirals in mucosal tissue
  publication-title: Expert Opin. Drug Metab. Toxicol.
  doi: 10.1517/17425255.2015.1027682
– volume: 108
  start-page: 4388
  year: 2011
  end-page: 4393
  ident: CR21
  article-title: Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1012861108
– volume: 46
  start-page: 3969
  year: 1986
  end-page: 3978
  ident: CR14
  article-title: Pharmacokinetics of monoclonal immunoglobulin G1, F(ab’)2, and Fab’ in mice
  publication-title: Cancer Res.
– volume: 98
  start-page: 3136
  year: 2001
  end-page: 3142
  ident: CR51
  article-title: Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect
  publication-title: Blood
  doi: 10.1182/blood.V98.10.3136
– volume: 28
  start-page: 1924
  year: 2022
  end-page: 1932
  ident: CR4
  article-title: Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-01953-6
– ident: CR30
– volume: 25
  start-page: 138
  year: 2018
  end-page: 142
  ident: CR24
  article-title: Maximizing the benefits of HIV preexposure prophylaxis
  publication-title: Top. Antivir. Med.
– volume: 205
  start-page: 2312
  year: 2020
  end-page: 2320
  ident: CR56
  article-title: Rapid collection of human rectal secretions using OriCol devices is suitable for measurement of mucosal Ig without blood contamination
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.2000320
– volume: 9
  start-page: e108954
  year: 2014
  ident: CR9
  article-title: The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0108954
– volume: 87
  start-page: 11604
  year: 2013
  end-page: 11616
  ident: CR11
  article-title: Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge
  publication-title: J. Virol.
  doi: 10.1128/JVI.01361-13
– volume: 54
  start-page: 1517
  year: 1994
  end-page: 1528
  ident: CR41
  article-title: Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice
  publication-title: Cancer Res.
– volume: 329
  start-page: 811
  year: 2010
  end-page: 817
  ident: CR2
  article-title: Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
  publication-title: Science
  doi: 10.1126/science.1192819
– volume: 139
  start-page: 3041
  year: 1987
  end-page: 3049
  ident: CR15
  article-title: Biodistribution of monoclonal IgG1, F(ab’)2, and Fab’ in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.139.9.3041
– volume: 15
  start-page: 187
  year: 2003
  end-page: 195
  ident: CR17
  article-title: RJ. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/dxg018
– volume: 514
  start-page: 642
  year: 2014
  end-page: 645
  ident: CR12
  article-title: Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
  publication-title: Nature
  doi: 10.1038/nature13612
– volume: 185
  start-page: 673
  year: 2009
  end-page: 684
  ident: CR19
  article-title: The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity
  publication-title: J. Cell Biol.
  doi: 10.1083/jcb.200809122
– volume: 29
  start-page: 2653
  year: 2013
  end-page: 2654
  ident: CR57
  article-title: nCal: an R package for non-linear calibration
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btt456
– volume: 10
  start-page: 1289
  year: 1998
  end-page: 1298
  ident: CR16
  article-title: Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/10.9.1289
– ident: CR34
– ident: CR28
– volume: 10
  year: 2019
  ident: CR46
  article-title: Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-12732-2
– volume: 13
  start-page: 45
  year: 2021
  end-page: 53
  ident: CR50
  article-title: Local genital arousal: Mechanisms for vaginal lubrication
  publication-title: Curr. Sex. Heath Rep.
  doi: 10.1007/s11930-021-00305-8
– volume: 63
  start-page: 263
  year: 2013
  end-page: 271
  ident: CR8
  article-title: Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility toward the anus
  publication-title: J. Acquir Immune Defic. Syndr.
  doi: 10.1097/QAI.0b013e3182898392
– volume: 491
  year: 2021
  ident: CR35
  article-title: A sensitive method to quantify HIV-1 antibodies in mucosal samples
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2021.112995
– volume: 16
  start-page: e0245638
  year: 2021
  ident: CR39
  article-title: Pixelwise H-score: A novel digital image analysis-based metric to quantify membrane biomarker expression from immunohistochemistry images
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0245638
– volume: 65
  start-page: 677
  year: 1992
  end-page: 683
  ident: CR40
  article-title: Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab’)2 fragments in experimental ovarian cancer
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.1992.144
– volume: 46
  start-page: 3969
  year: 1986
  ident: 54580_CR14
  publication-title: Cancer Res.
– volume: 42
  start-page: 93
  year: 1999
  ident: 54580_CR58
  publication-title: J. Reprod. Immunol.
  doi: 10.1016/S0165-0378(98)00086-2
– volume: 108
  start-page: 4388
  year: 2011
  ident: 54580_CR21
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1012861108
– volume: 96
  start-page: 764
  year: 1989
  ident: 54580_CR25
  publication-title: Gastroenterology
– volume: 63
  start-page: 263
  year: 2013
  ident: 54580_CR8
  publication-title: J. Acquir Immune Defic. Syndr.
  doi: 10.1097/QAI.0b013e3182898392
– volume: 6
  year: 2021
  ident: 54580_CR55
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-021-00305-8
– volume: 104
  start-page: 538
  year: 1996
  ident: 54580_CR29
  publication-title: Clin. Exp. Immunol.
  doi: 10.1046/j.1365-2249.1996.36742.x
– volume: 98
  start-page: 3136
  year: 2001
  ident: 54580_CR51
  publication-title: Blood
  doi: 10.1182/blood.V98.10.3136
– volume: 353
  start-page: 1045
  year: 2016
  ident: 54580_CR53
  publication-title: Science
  doi: 10.1126/science.aag0491
– ident: 54580_CR60
  doi: 10.1242/dmm.035147
– volume: 15
  start-page: e1002493
  year: 2018
  ident: 54580_CR5
  publication-title: PLoS Med.
  doi: 10.1371/journal.pmed.1002493
– volume: 205
  start-page: 2312
  year: 2020
  ident: 54580_CR56
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.2000320
– volume: 10
  start-page: 1289
  year: 1998
  ident: 54580_CR16
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/10.9.1289
– volume: 14
  start-page: 850
  year: 2012
  ident: 54580_CR47
  publication-title: AAPS J.
  doi: 10.1208/s12248-012-9395-9
– volume: 102
  start-page: 571
  year: 2003
  ident: 54580_CR59
  publication-title: Obstet. Gynecol.
– volume: 9
  start-page: e1003776
  year: 2013
  ident: 54580_CR32
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1003776
– volume: 26
  start-page: 257
  year: 2007
  ident: 54580_CR7
  publication-title: Immunity
  doi: 10.1016/j.immuni.2007.01.007
– volume: 14
  start-page: e1002435
  year: 2017
  ident: 54580_CR38
  publication-title: PLoS Med.
  doi: 10.1371/journal.pmed.1002435
– volume: 7
  start-page: 1036
  year: 2014
  ident: 54580_CR52
  publication-title: Mucosal Immunol.
  doi: 10.1038/mi.2013.120
– volume: 87
  start-page: 11604
  year: 2013
  ident: 54580_CR11
  publication-title: J. Virol.
  doi: 10.1128/JVI.01361-13
– volume: 40
  start-page: 597
  year: 2013
  ident: 54580_CR44
  publication-title: J. Pharmacokinet. Pharmacodyn.
  doi: 10.1007/s10928-013-9332-2
– volume: 9
  start-page: e108954
  year: 2014
  ident: 54580_CR9
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0108954
– volume: 166
  start-page: 3266
  year: 2001
  ident: 54580_CR31
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.166.5.3266
– volume: 10
  start-page: 1540
  year: 2019
  ident: 54580_CR22
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.01540
– volume: 329
  start-page: 856
  year: 2010
  ident: 54580_CR1
  publication-title: Science
  doi: 10.1126/science.1187659
– volume: 491
  year: 2021
  ident: 54580_CR35
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2021.112995
– volume: 139
  start-page: 3041
  year: 1987
  ident: 54580_CR15
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.139.9.3041
– volume: 450
  start-page: 66
  year: 2017
  ident: 54580_CR42
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2017.07.009
– volume: 10
  start-page: e042247
  year: 2020
  ident: 54580_CR54
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2020-042247
– volume: 12
  start-page: 33
  year: 2010
  ident: 54580_CR20
  publication-title: AAPS J.
  doi: 10.1208/s12248-009-9157-5
– volume: 15
  start-page: 187
  year: 2003
  ident: 54580_CR17
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/dxg018
– volume: 13
  start-page: 45
  year: 2021
  ident: 54580_CR50
  publication-title: Curr. Sex. Heath Rep.
  doi: 10.1007/s11930-021-00305-8
– volume: 11
  year: 2021
  ident: 54580_CR61
  publication-title: Front. Cell Infect. Microbiol.
  doi: 10.3389/fcimb.2021.733619
– volume: 6
  start-page: 576
  year: 2017
  ident: 54580_CR18
  publication-title: CPT Pharmacomet. Syst. Pharm.
  doi: 10.1002/psp4.12224
– volume: 12
  year: 2021
  ident: 54580_CR6
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.712122
– volume: 13
  year: 2022
  ident: 54580_CR43
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-28727-5
– volume: 10
  year: 2019
  ident: 54580_CR46
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-12732-2
– volume: 182
  start-page: 289
  year: 2015
  ident: 54580_CR36
  publication-title: Clin. Exp. Immunol.
  doi: 10.1111/cei.12692
– volume: 10
  start-page: e0132942
  year: 2015
  ident: 54580_CR45
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0132942
– volume: 85
  start-page: 97
  year: 2011
  ident: 54580_CR48
  publication-title: Biol. Reprod.
  doi: 10.1095/biolreprod.110.090423
– ident: 54580_CR30
– volume: 71
  start-page: 618
  year: 2014
  ident: 54580_CR49
  publication-title: Am. J. Reprod. Immunol.
  doi: 10.1111/aji.12230
– volume: 11
  year: 2021
  ident: 54580_CR27
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-02954-0
– volume: 65
  start-page: 677
  year: 1992
  ident: 54580_CR40
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.1992.144
– volume: 207
  start-page: 505
  year: 2021
  ident: 54580_CR13
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.2100253
– ident: 54580_CR34
  doi: 10.1172/jci146975
– volume: 10
  start-page: 144
  year: 2019
  ident: 54580_CR10
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.00144
– volume: 11
  start-page: 893
  year: 2015
  ident: 54580_CR23
  publication-title: Expert Opin. Drug Metab. Toxicol.
  doi: 10.1517/17425255.2015.1027682
– volume: 28
  start-page: 1924
  year: 2022
  ident: 54580_CR4
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-01953-6
– volume: 514
  start-page: 642
  year: 2014
  ident: 54580_CR12
  publication-title: Nature
  doi: 10.1038/nature13612
– ident: 54580_CR28
– volume: 89
  start-page: 405
  year: 2022
  ident: 54580_CR33
  publication-title: J. Acquir Immune Defic. Syndr.
  doi: 10.1097/QAI.0000000000002892
– volume: 329
  start-page: 811
  year: 2010
  ident: 54580_CR2
  publication-title: Science
  doi: 10.1126/science.1192819
– volume: 164
  start-page: S39
  year: 2001
  ident: 54580_CR26
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/ajrccm.164.supplement_2.2106065
– volume: 16
  start-page: e0245638
  year: 2021
  ident: 54580_CR39
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0245638
– volume: 185
  start-page: 673
  year: 2009
  ident: 54580_CR19
  publication-title: J. Cell Biol.
  doi: 10.1083/jcb.200809122
– volume: 28
  start-page: 1022
  year: 2022
  ident: 54580_CR37
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-01762-x
– volume: 54
  start-page: 1517
  year: 1994
  ident: 54580_CR41
  publication-title: Cancer Res.
– volume: 25
  start-page: 138
  year: 2018
  ident: 54580_CR24
  publication-title: Top. Antivir. Med.
– volume: 384
  start-page: 1003
  year: 2021
  ident: 54580_CR3
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2031738
– volume: 29
  start-page: 2653
  year: 2013
  ident: 54580_CR57
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btt456
SSID ssj0000391844
Score 2.468566
Snippet To prevent sexually-acquired HIV-1 infection by immunoprophylaxis, effective concentrations of broadly neutralizing antibodies are likely needed at mucosal...
Abstract To prevent sexually-acquired HIV-1 infection by immunoprophylaxis, effective concentrations of broadly neutralizing antibodies are likely needed at...
SourceID doaj
proquest
pubmed
crossref
springer
SourceType Open Website
Aggregation Database
Index Database
Publisher
StartPage 10332
SubjectTerms 13/1
13/106
631/250/251/1567
631/250/2520
631/250/347
692/699/255/1901
82/51
Adult
Antibodies
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - pharmacokinetics
Antibodies, Neutralizing - immunology
Biodistribution
Biological effects
Blood levels
Broadly Neutralizing Antibodies - immunology
Disease transmission
Female
Genital tract
Half-Life
HIV
HIV Antibodies - immunology
HIV Infections - immunology
HIV Infections - prevention & control
HIV Infections - virology
HIV-1 - immunology
Human immunodeficiency virus
Humanities and Social Sciences
Humans
Immunoprophylaxis
Intestinal Mucosa - immunology
Intestinal Mucosa - metabolism
Intravenous infusion
Lamina propria
Male
Middle Aged
Monoclonal antibodies
Mucosa
Mucous Membrane - immunology
Mucous Membrane - metabolism
Mucous Membrane - virology
multidisciplinary
Neutralizing
Rectum
Rectum - virology
Science
Science (multidisciplinary)
Secretions
Sexually transmitted diseases
STD
Stroma
Tissue Distribution
Tissues
Vagina - immunology
Vagina - virology
Young Adult
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYQEhKXqjyb8pArcSsWiV-xj4BA26pwaAFxs_yKuocmiN09wK9n7GQXKkC99JbEjl-fM_M5Y88gdCCY06xxFWlAvxMeuCfWMk2CVlLLIDzNp1wvLuXomn-_FbcvQn2lPWG9e-B-4I4ilAUkP0Qpay597QJwEumtcJYC2WmS9AWd92IxlWUw07B04cMpmZKpownPMgFUEkm2opLovzRRdtj_Fst8ZSHNiuf8I_owMEZ83Ld0DS3Fdh2t9DEkHzbQ3Vn7O1vxsW0DnvTnoeDOjbuQnOIO8axw1-DRtxtS4TbO8t-NR6gN3pmOXRce8M3P07L68QuPW5zD9mGYWCmeSC41SUW4_JN2t9tNdH1-dnU6IkMYBeI5k1NCIwDCRVNGXwpQ2FpRJxXQRBl03dRAOSgFJG3V8Fg5H2uArtbBySqoaJlnW2i57dr4CWFGo3ROKEj1nDvQ9lwJW0KmmI7E2gJ9nQ-pueu9ZZhs5WbK9AAYAMBkAIwu0Eka9UXO5Ok6PwD8zYC_-Rf-BdqdY2aGz29iWFp5S6ko1PFlkQwfTrKG2DZ2s5yHJ_f3ghVou8d60RKW_PCBdCvQ4Rz858Lf79Dn_9GhHbRK0yytKkLVLlqe3s_iHhCfqdvPc_wJpFn8Nw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZKERIX1PIMtMhI3MCQ-BX7gBBUrRZEOQBb9Wb5lbISJGUfUpdfz9hJFiEWbnk4ceJvxvM5k5lB6KlgTrPGVaQB-0544J5YyzQJWkktg_A0R7mefpSTKX9_Ls530FjuaBjAxdalXaonNZ1_e3H1Y_0aFP5VHzKuXi54VnewNiS5gUqir6HrYJnqpKinA93PMzPTsKDhQ-zM9kv_sE85jf827vmX3zSbo5M9dGvgkfhND_w-2ontbXSjryy5voMuj9uv2bePbRvwoo-Sgj0360JKlTtUucJdgyfvzkiF27jK3zx-Qm9wzXLmurDGZ5-OyurDZzxrcS7mh0HcUpWRfNc0V8Lm9_TPu72LpifHX44mZCiuQDxnckloBJi4aMroSwGDpRV1UgF5lEHXTQ1EhFLA11YNj5XzsQZAax2crIKKlnl2D-22XRsfIMxolM4JBWc95w44AFfCltAopkBZW6Bn45Cayz6Hhsm-b6ZMD4ABAEwGwOgCvU2jvmmZ8l_nA938wgzqZCJIGCz9QpSy5tLXLgBTld4KZylQ4KZAByNmZpQpw9J6XEpFoY8nm9OgTslHYtvYrXIbnpLiC1ag-z3WmydhKTsfzHkFej6C__vm_36hh_9_lkfoJk3yV1WEqgO0u5yv4iEQnaV7nKX3F1Nk9tA
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6VIiQuiDeBgozEDSwSv2IfYdVqQcABaNWb5VdgDyRVd_fQ_vqOnWQRohy4JbETJ_7GnnHG8w3AK8m94Z1vaIf6nYooAnWOGxqNVkZFGViJcv38RS2PxcdTeboHbI6FKZv2C6Vlmabn3WFv16IMadQoNLt6ampuwM1M3Z6leqEWu_8qmfFcCzHFx9RcX3PrHzqoUPVfZ1_-5RstKufoLtyZbEXybny7e7CX-vtwa8weefEAzg77n8V_T1wfyXqMhMIzvxpipsOdMlmRoSPLDye0IX3alv8al9ga3rNZ-SFekJOvi7r59I2selIS9hEUqZxJpDw1z4d4-Cvva3cP4fjo8PtiSacECjQIrjaUJYRCyK5OoZaoqo1mXmk0EFU0bdeiscEYYuiaTqTGh9QiaK2JXjVRJ8cDfwT7_dCnJ0A4S8p7qbE0COFRzwstXY2VUg6GdRW8nrvUno08Gbb4t7m2IwAWAbAFAGsqeJ97fVczc1yXC8P5DzthbhNKES7vYlKqFSq0PqI1qoKT3jE0c7sKDmbM7DTw1pbnNbdSmmEbL3fFOGSyH8T1adiWOiIT30teweMR692b8MzAh_NaBW9m8H8__N8f9PT_qj-D2yzLY9NQpg9gf3O-Tc_RuNn4F0WarwB4u_Fu
  priority: 102
  providerName: Springer Nature
Title Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa
URI https://link.springer.com/article/10.1038/s41467-024-54580-9
https://www.ncbi.nlm.nih.gov/pubmed/39609400
https://www.proquest.com/docview/3133866829
https://www.proquest.com/docview/3134066253
https://doaj.org/article/eb93619de66746c7bd1926ca5ba2800f
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxELagFRIXxJstJTISN7C6a3u99gmlUUKIaIVaWuVm-bUlB3bTJjmUX8_Yu0mFeFz24fV6H994ZjxjzyD0rmRWsdoWpAb5TrjnjhjDFPFKCiV86Wha5XpyKqYXfDYv573BbdVPq9zyxMSofeuijfyIxcGUEJKqj8trErNGRe9qn0LjPtqPocvilK5qXu1sLDH6ueS8XyuTM3m04okzgGAi0WOUE_WbPEph-_-ma_7hJ03iZ_IYPer1RjzsgH6C7oXmKXrQZZK8fYaW4-Z78uVj03i86lZFwZldtD6Gxu2zWuG2xtPPl6TATdgkG8dPeBrcs17Y1t_iy7NRXnw5x4sGp-R9GMgrZhVJrUbeCIc_4hx38xxdTMbfRlPSJ1MgjjOxJjQALLys8-DyEsS2ktQKCcqi8KqqK1A8KAU8TVHzUFgXKgCwUt6KwstgmGMv0F7TNuEVwowGYW0p4arj3ILM57I0OVQKcWGsydD77S_Vyy5mhk6-biZ1B4AGAHQCQKsMHce_vqsZ412ngvbmSvfdRwegKBjq-SBExYWrrAfNVDhTWkNB5a0zdLjFTPedcKXvSCZDb3eXoftEn4hpQrtJdXgMgl-yDL3ssN69CYvR-IDHZejDFvy7xv_9QQf_f5fX6CGN9FcUhMpDtLe-2YQ3oNis7SBRL2zl5NMA7Q-Hs_MZ7I_Hp1_PoHQkRoNkMoDtCZe_AHfy-l4
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFH8aQwguiG8CA4wEJ7CW2I6THBCCsall3Q6wTbsZfwV6IClrK1T-KP5Gnp2kE-LjtlvbuI7t92k_v_cDeJZzU_HaZLRG-06FE5ZqzSvqqlJW0uWWxSzXg0M5OhbvT_PTDfg55MKEa5WDToyK2rU2nJFv87CZkrJk1evZNxpQo0J0dYDQ6Nhi36--45Zt_mr8Dun7nLG93aOdEe1RBagVXC4o8zg-kdept2mO9qsqmZElek3SVUVdoAVmDCems1r4zFhf4EyKyhmZudJrbjn2ewkuo-FNg0QVp8X6TCdUWy-F6HNzUl5uz0XURGgIaYhQpbT6zf5FmIC_-bZ_xGWjudu7Add7P5W86RjrJmz45hZc6ZArV7dhttt8iXcHiG4cmXdZWPjNTFsXSvH2KFqkrclofEIz0vhlPFP5gW_D_yympnUrcvJhJ80mH8m0IREskCA7BxST2GvQxfjxa7hTr-_A8YUs813YbNrG3wfCmZfG5CU-tUIY9DFEmesUG_mQiKsTeDEsqZp1NTpUjK3zUnUEUEgAFQmgqgTehlVftwz1teMP7dln1Yur8sjBuLV0XspCSFsYh56wtDo3mqGLXSewNdBM9UI_V-csmsDT9WMU1xCD0Y1vl7GNCEX3c57AvY7W65HwUP0PdWoCLwfin3f-7wk9-P9YnsDV0dHBRE3Gh_sP4RoLvBhzKbdgc3G29I_QqVqYx5GTCXy6aNH5Bf4GMJ8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1Lb9Mw-NMYAnFBvAkMMBKcwGpiO45zQAi2VS0bEwI29Wbs2IEeSMraCpWfxq_js5N2Qjxuu-XhOLa_p_29AJ7k3Ja8thmtUb5T4URFjeEldaWSpXR5xWKU69sjOToWbyb5ZAt-rmNhglvlmidGRu3aKpyRD3jYTEmpWDmoe7eId3vDl7NvNFSQCpbWdTmNDkUO_Oo7bt_mL8Z7COunjA33P-6OaF9hgFaCywVlHscq8jr1VZqjLCsVs1KhBiVdWdQFSmPGcJImq4XPbOULnFVROiszp7zhFcd-L8DFgudZoLFiUmzOd0LmdSVEH6eTcjWYi8iVUCjSYK1KafmbLIwlA_6m5_5ho42ib3gNrvY6K3nVIdl12PLNDbjUVbFc3YTZfvMl-hEQ0zgy7yKy8M5OWxfS8vYVtUhbk9H4hGak8ct4vvID_4bfLKa2dSty8n43zQ4_kGlDYuFAgqgdKprEXgNfxsuvwb_e3ILjc1nm27DdtI2_C4QzL63NFb6thLCobwiVmxQb-RCUaxJ4tl5SPevydehoZ-dKdwDQCAAdAaDLBF6HVd-0DLm244P29LPuSVd7xGbcZjovZSFkVViHWrGsTG4NQ3W7TmBnDTPdM4C5PkPXBB5vXiPpBnuMaXy7jG1ESMCf8wTudLDejISHTIDIXxN4vgb-Wef_ntC9_4_lEVxGotGH46OD-3CFBVTMMsrUDmwvTpf-AepXC_swIjKBT-dNOb8AQ2E03g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enhanced+and+sustained+biodistribution+of+HIV-1+neutralizing+antibody+VRC01LS+in+human+genital+and+rectal+mucosa&rft.jtitle=Nature+communications&rft.au=Lemos%2C+Maria+P&rft.au=Astronomo%2C+Rena+D&rft.au=Huang%2C+Yunda&rft.au=Narpala%2C+Sandeep&rft.date=2024-11-28&rft.pub=Nature+Publishing+Group&rft.eissn=2041-1723&rft.volume=15&rft.issue=1&rft.spage=10332&rft_id=info:doi/10.1038%2Fs41467-024-54580-9&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon